Bevacizumab: a New Way of Doing Business. Part 2
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Shalaby A, Lewis K, Bush K, Meredith P, Di Simplicio S, Lockwood A
. Licence to save: a UK survey of anti-VEGF use for the eye in 2015. Eye (Lond). 2016; 30(11):1404-1406.
PMC: 5108014.
DOI: 10.1038/eye.2016.154.
View
2.
Canning C, Lotery A
. Bevacizumab: a new way of doing business?. Eye (Lond). 2006; 20(9):985-7.
DOI: 10.1038/sj.eye.6702501.
View
3.
Chakravarthy U, Harding S, Rogers C, Downes S, Lotery A, Culliford L
. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 2013; 382(9900):1258-67.
DOI: 10.1016/S0140-6736(13)61501-9.
View
4.
Almuhtaseb H, Johnston R, Talks J, Lotery A
. Second-year visual acuity outcomes of nAMD patients treated with aflibercept: data analysis from the UK Aflibercept Users Group. Eye (Lond). 2017; 31(11):1582-1588.
PMC: 5684449.
DOI: 10.1038/eye.2017.108.
View
5.
Lotery A, MacEwen C
. What is stopping the NHS from using bevacizumab for macular degeneration and other retinal disorders?. BMJ. 2014; 349:g6887.
DOI: 10.1136/bmj.g6887.
View